利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

1122 条记录 (耗时 0.11 秒)

    METHODS AND COMPOSITIONS FOR USE IN TREATMENT OF SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) PATIENTS WITH AUTOANTIBODY POSITIVE DISEASES
    3.
    发明公开
    METHODS AND COMPOSITIONS FOR USE IN TREATMENT OF SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) PATIENTS WITH AUTOANTIBODY POSITIVE DISEASES 审中-公开
    方法和组合物中的系统性红斑狼疮患者的自身抗体阳性莱顿治疗

    公开(公告)号：EP3037544A1

    公开(公告)日：2016-06-29

    申请号：EP15190050.3

    申请日：2006-10-05

    申请人： Human Genome Sciences, Inc.

    发明人： CHEVRIER, Marc ,  FRIEMUTH, William ,  ZHONG, Zhenshao ,  ODENHEIMER, Daniel ,  PERKINS, Melissa D.

    IPC分类号： C12P21/06 ,  C07H21/04 ,  C07K16/00 ,  A61K39/395 ,  A61K49/00

    CPC分类号： C07K16/2875 ,  A61K38/185 ,  A61K2039/505 ,  A61K2039/507 ,  C07K14/70575 ,  C07K2317/56 ,  C07K2317/73

    摘要： The present invention relates to methods and compositions for use in treatment of patients with autoantibody positive disease. In a specific embodiment, the present invention relates to a method of treating a patient that has an ANA titer of 1:80 or greater and/or greater than or equal to 30 IU/ml of anti-dsDNA antibodies in his/her blood plasma or serum comprising administering a therapeutically effective amount of an immunomodulatory agent, such as an antagonist of Neutrokine-alpha. Additionally provided is a method of reducing the frequency and/or quantity of corticosteroid administration to patients. In preferred embodiments, the patient has systemic lupus erythematosus. Methods for determining if a lupus patient is responding to medical treatment are also provided.

    摘要翻译： 本发明涉及用于在治疗患者的自身抗体阳性疾病使用方法和组合物。 在一个具体的实施方案，本发明涉及治疗患者的方法确实具有的1:80或更大和/或大于或等于30 IU / mL，在他/她的血浆抗dsDNA抗体的滴度ANA 或血清，包括给予治疗有效量的免疫调节剂，如在Neutrokine-α拮抗剂测试。 另外提供的是皮质类固醇减少的给药频率和/或数量的患者的方法。 在优选的实施方案中，所述患者具有全身性红斑狼疮。 因此，提供用于确定性挖掘方法，如果一个狼疮患者正在响应治疗。

    Albumin fusion proteins
    6.
    发明公开
    Albumin fusion proteins 审中-公开
    白蛋白Fusionsproteine

    公开(公告)号：EP2474318A1

    公开(公告)日：2012-07-11

    申请号：EP12153218.8

    申请日：2007-06-07

    申请人： Human Genome Sciences, Inc.

    发明人： Rosen, Craig A. ,  Lafleur, David W.

    IPC分类号： A61K38/26 ,  C12N15/62 ,  C07K14/765

    CPC分类号： C12N9/96 ,  A61K38/00 ,  C07K14/765 ,  C07K2319/00 ,  C12N15/62

    摘要： The present invention encompasses albumin fusion proteins. Nucleic acid molecules encoding the albumin fusion proteins of the invention are also encompassed by the invention, as are vectors containing these nucleic acids, host cells transformed with these nucleic acids vectors, and methods of making the albumin fusion proteins of the invention and using these nucleic acids, vectors, and/or host cells. Additionally the present invention encompasses pharmaceutical compositions comprising albumin fusion proteins and methods of treating, preventing, or ameliorating diseases, disorders or conditions using albumin fusion proteins of the invention.

    摘要翻译： 本发明包括白蛋白融合蛋白。 编码本发明的白蛋白融合蛋白的核酸分子也包括在本发明中，以及含有这些核酸的载体，用这些核酸载体转化的宿主细胞以及制备本发明的白蛋白融合蛋白并使用这些核酸的方法 酸，载体和/或宿主细胞。 另外，本发明包括含有白蛋白融合蛋白的药物组合物和使用本发明的白蛋白融合蛋白治疗，预防或改善疾病，病症或病症的方法。

    ANTIBODIES THAT SPECIFICALLY BIND TO CHEMOKINE BETA-4
    8.
    发明授权
    ANTIBODIES THAT SPECIFICALLY BIND TO CHEMOKINE BETA-4 有权
    具体趋化因子β-4结合抗体

    公开(公告)号：EP1534752B1

    公开(公告)日：2011-08-03

    申请号：EP03721955.7

    申请日：2003-04-30

    申请人： Human Genome Sciences, Inc.

    发明人： ROSEN, Craig, A. ,  RUBEN, Steven, M.

    IPC分类号： C07K16/00 ,  C07K16/24

    CPC分类号： C07K16/24 ,  A61K2039/505 ,  C07K2317/21 ,  C07K2317/565 ,  C07K2317/622 ,  C07K2317/76 ,  C07K2317/92

    摘要： The present invention relates to antibodies and related molecules that specifically bind to CK-B4. Such antibodies have uses, for example, in the prevention and treatment of cancer as well as immune system diseases and disorders including cancers, as well as immune system diseases and disorders including autoimmune diseases, inflammatory disorders, immunodeficiencies, infections, HIV, arthritis, allergy, psoriasis, dermatitis, and inflammatory bowel disease. The invention also relates to nucleic acid molecules encoding anti-CK-B4 antibodies, vectors and host cells containing these nucleic acids, and methods for producing the same. The present invention relates to methods and compositions for preventing, detecting, diagnosing, treating or ameliorating a disease or disorder, especially cancers, as well as immune system diseases and disorders including autoimmune disease, inflammatory disorders, immunodeficiencies, infections, HIV, arthritis, allergy, psoriasis, dermatitis, and inflammatory bowel disease, comprising administering to an animal, preferably a human, an effective amount of one or more antibodies or fragments or variants thereof, or related molecules, that specifically bind to CK-B4.